This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Adult Male Subjects

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: January 7, 2009
Last updated: March 6, 2009
Last verified: March 2009
This is a phase 1 study to assess the routes of elimination of a single oral dose of [14C] PF-00868554 and to characterize the metabolic profile following single dose administration.

Condition Intervention Phase
HCV Drug: [14C]-PF-00868554 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Phase 1 Study To Evaluate The Metabolism And Excretion Of [14C] PF-00868554 In Healthy Adult Male Subjects

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • The amount of radioactivity recovered in urine and feces, as a percent of the dose. [ Time Frame: 7 weeks ]
  • The amount of PF-00868554, expressed as a percent of total radioactivity, in plasma, urine, and feces. [ Time Frame: 7 weeks ]
  • Identification and determination of relative abundance of the metabolites of PF-00868554 in plasma, urine, and feces. [ Time Frame: 7 weeks ]
  • PK parameters: AUClast, AUCinf, maximum concentration (Cmax), time of maximum concentration (Tmax), and half-life (t1/2) to describe the single dose PK of a) total radioactivity in blood; b) total radioactivity in plasma; c) PF-00868554 in plasma. [ Time Frame: 7 weeks ]

Secondary Outcome Measures:
  • Safety endpoints including adverse events, clinical laboratory tests, vital signs and ECGs. [ Time Frame: 7 weeks ]

Enrollment: 7
Study Start Date: January 2009
Study Completion Date: February 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: [14C]-PF-00868554
solution, single dose


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male, healthy volunteers.

Exclusion Criteria:

  • Females.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00823745

United States, Washington
Pfizer Investigational Site
Tacoma, Washington, United States, 98415
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc. Identifier: NCT00823745     History of Changes
Other Study ID Numbers: A8121013
Study First Received: January 7, 2009
Last Updated: March 6, 2009 processed this record on September 21, 2017